Endothelin receptor antagonists (ERAs) can potentially be used as therapeutic drugs to reduce hypertension caused by small molecule tyrosine kinase inhibitors (TKIs)

Endothelin receptor antagonists (ERAs) can potentially be used as therapeutic drugs to reduce hypertension caused by small molecule tyrosine kinase inhibitors (TKIs)

The emergence of targeted anti-tumor drugs has significantly prolonged the lifespan and improved the prognosis of cancer patients. Among these drugs, vascular endothelial growth factor (VEGF) inhibitors, particularly novel small molecule tyrosine kinase inhibitors (TKIs), are extensively employed as...

Full description

Saved in:
Bibliographic Details
Main Authors: Qingjian He, Junling Lin, Chanjuan Mo, Guodong Li, Jianzhong Lu, Qiyin Sun, Lijun Cao, Haojian Gan, Quan Sun, Jiafang Yao, Shengyi Lian, WenJuan Wang
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-01-01
Series:Frontiers in Pharmacology
Subjects:
hypertension
tyrosine kinase inhibitors
endothelin receptor antagonists
endothelin
aprocitentan
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2024.1463520/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2024.1463520/full

Similar Items